Altimmune, Inc.ALTNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank13
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P13
Within normal range
vs 2Y Ago
-3.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-63.47%
Q3 202539.45%
Q2 2025-16.67%
Q1 20257.80%
Q4 202432.65%
Q3 2024-49.76%
Q2 2024-10.70%
Q1 20241.06%
Q4 202319.30%
Q3 2023-4.71%
Q2 2023-0.81%
Q1 2023-12.14%
Q4 2022-14.99%
Q3 20229.90%
Q2 2022-23.50%
Q1 202238.43%
Q4 2021-23.58%
Q3 20216.09%
Q2 20213.28%
Q1 2021-45.89%
Q4 2020-41.12%
Q3 2020-32.55%
Q2 2020-64.95%
Q1 2020-117.15%
Q4 201917.50%
Q3 201920.70%
Q2 2019-44.83%
Q1 201959.02%
Q4 2018-403.97%
Q3 2018-393.83%
Q2 2018109.78%
Q1 201825.96%
Q4 2017-12.85%
Q3 2017-5.05%
Q2 201742.87%
Q1 2017-108.56%
Q4 2016-25.66%
Q3 20161205.24%
Q2 2016730.15%
Q1 201625.91%